As of January 22, 2025, Kronos Bio (KRON) has a market cap of $60.944 million USD. According to our data, Kronos Bio is ranked No.8040 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $60.94 M |
6.32%
|
Dec 31, 2024 | $57.32 M |
-24.00%
|
Dec 29, 2023 | $75.43 M |
-22.84%
|
Dec 30, 2022 | $97.75 M |
-88.08%
|
Dec 31, 2021 | $0.82 B |
-54.50%
|
Dec 31, 2020 | $1.80 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.77 B |
0.000 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Incyte
INCY
|
$13.95 B |
-0.000 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Exelixis
EXEL
|
$9.39 B |
0.000 M
|
USA
|
Blueprint Medicines
BPMC
|
$7.06 B |
-0.000 M
|
USA
|
Agios Pharmaceuticals
AGIO
|
$1.94 B |
-0.000 M
|
USA
|
MacroGenics
MGNX
|
$0.20 B |
-0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Relay Therapeutics
RLAY
|
$0.82 B |
0.000 M
|
USA
|
Market Cap | = | KRON Stock Price | * | KRON Shares Outstanding |
= | $1.01 | * | 60.34 M | |
= | $60.94 M |